贵州三力制药股份有限公司 2023年度审计委员会履职情况报告 根据《上市公司治理准则》、《上海证券交易所股票上市规则（2023 年 8 月修订）》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作 （2023 年 12 月修订）》、《贵州三力制药股份有限公司章程》（以下简称 "《公司章程》"）等有关规定，贵州三力制药股份有限公司(以下简称"公 司")第三届董事会审计委员会在 2023 年度本着勤勉尽责的原则，积极开展工 作，认真履行了职责。 现将公司 2023 年度董事会审计委员会工作情况汇报如下： 一、董事会审计委员会会议召开情况 委员严格按照《公司章程》和《董事会审计委员会议事规则》的规定行使 自己的权利和履行自己的义务。2023 年度，公司董事会审计委员会共召开了 6 次会议，全体委员均亲自出席了会议，本着勤勉尽责的态度，认真履行职责， 积极对相关议题发表了意见，并对相关决议进行了签字确认。具体情况如下： | 序号 | 会议名称 | 召开时间 | 审议事项 | | --- | --- | --- | --- | | 1 | 第三届董事会 审计委员会第 | 2023/4/13 | 《公司2022 ...

Financial Performance - The audited net profit attributable to shareholders for 2023 is CNY 292,702,869.34, with the parent company's distributable profit at CNY 694,947,388.84[4] - In 2023, the company's operating revenue reached RMB 1.63 billion, a year-on-year increase of 36.10%[21] - The net profit attributable to shareholders was RMB 292.70 million, up 45.42% compared to the previous year[21] - The net profit after deducting non-recurring gains and losses was RMB 245.65 million, reflecting a 26.21% increase year-on-year[21] - Total assets increased by 60.76% year-on-year, reaching RMB 2.92 billion, primarily due to the mergers with Hanfang Pharmaceutical and Wudi Pharmaceutical[21] - The weighted average return on equity rose to 21.45%, an increase of 3.71 percentage points from the previous year[22] - The company achieved a net cash flow from operating activities of RMB 276.70 million, a decrease of 5.65% compared to the previous year[21] - The company’s equity attributable to shareholders increased by 18.66% year-on-year, amounting to RMB 1.47 billion[21] - The company reported a significant increase in manufacturing costs for the pharmaceutical sector, rising by 207.64% to CNY 51,076,010.22[71] - The company reported a total of 2,282 employees, with 1,316 in the parent company and 966 in major subsidiaries[157] Profit Distribution - The proposed profit distribution plan for 2023 is a cash dividend of CNY 2.00 per 10 shares (tax included), with no bonus shares or capital reserve conversion[4] - The total cash dividend amount, including the repurchase of shares, is RMB 111,645,063.20, accounting for 38.14% of the net profit attributable to ordinary shareholders in the consolidated financial statements[164] - The total cash dividend to be distributed is RMB 81,650,263.20, which represents a cash dividend ratio of 27.90% of the net profit attributable to ordinary shareholders in the consolidated financial statements[161] Compliance and Governance - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting potential risks[5] - The company confirms that there are no violations in decision-making procedures for external guarantees[7] - The board of directors and management guarantee the authenticity and completeness of the annual report, with no significant omissions[10] - The company operates under the regulatory guidance of the China Securities Regulatory Commission and the Shanghai Stock Exchange[13] - The company has held four shareholder meetings in 2023, ensuring compliance with legal and regulatory requirements[141] Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings, particularly in the OTC and traditional medicine sectors[13] - The company has diversified its product structure and expanded its marketing team to enhance OTC channel development[29] - The company expanded its sales channels, adding over 700 hospital channels and 600 small chain pharmacies, significantly boosting product sales stability[36] - The company is actively collaborating with hospitals and universities for clinical research, enhancing the evidence base for its core products and addressing the efficacy of traditional Chinese medicine[38] - The company is committed to exploring mergers and acquisitions in the health sector to drive significant growth and expand its pharmaceutical footprint[132] Research and Development - The company is committed to advancing digital production and research transformation to enhance its core competitiveness in the traditional Chinese medicine sector[39] - The company has established long-term strategic partnerships with multiple research institutions and universities to improve product quality and safety, focusing on new product development and existing product evaluations[55] - The company is conducting a multi-center clinical trial for its core product, the throat spray, expected to be completed within three years[96] - The company is developing several new traditional Chinese medicine products, including Xie Bai San and Qiang Huo Sheng Shi Tang, which are currently in the pharmaceutical research stage[100] - The company has ongoing research on the efficacy and safety of the "Qi Jiao Sheng Bai Capsule," which is aimed at treating symptoms related to blood deficiency, with plans for market launch after further studies[105] Environmental Responsibility - The company invested CNY 3.71 million in environmental protection during the reporting period[171] - The wastewater treatment facility has a capacity of 100 tons per day, achieving over 98% removal rates for COD and ammonia nitrogen[174] - The company has a dedicated hazardous waste storage facility, managed by specialized personnel, ensuring compliance with pollution control standards[176] - The company has established emergency response plans for environmental incidents, filed with local environmental protection agencies[178] - The company has a comprehensive environmental self-monitoring plan in place, ensuring regular assessments of emissions and wastewater quality[180] Human Resources and Management - The company has a structured management team with a mix of experienced professionals, ensuring continuity in leadership and strategic direction[143] - The total remuneration for the reporting period for directors and senior management amounted to 437.83 million yuan[143] - The company has implemented a performance-based compensation system linked to job value and contribution, enhancing its incentive mechanisms[158] - The company conducted 123 training sessions during the reporting period to enhance employee skills and strengthen corporate culture[160] - The company has a stock incentive plan in place, with 2,540,000 restricted shares granted to key management personnel, of which 1,016,000 shares have been unlocked[166]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 422,024,144.62, representing a year-on-year increase of 20.93%[5] - The net profit attributable to shareholders for the same period was CNY 56,048,131.61, with a growth of 2.03% compared to the previous year[5] - The basic earnings per share (EPS) was CNY 0.14, reflecting an increase of 7.69% year-on-year[5] - The net profit for Q1 2024 was ¥56,860,529.64, representing a 6.9% increase from ¥53,396,249.70 in Q1 2023[17] - In Q1 2024, the company reported a net profit of 56,860,529.64 RMB, an increase from 53,396,249.70 RMB in Q1 2023, representing a growth of approximately 4.3%[18] - The overall comprehensive income attributable to the parent company was 56,048,131.61 RMB in Q1 2024, up from 54,932,724.23 RMB in Q1 2023, reflecting a growth of approximately 2%[18] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to CNY 2,946,600,361.23, a slight increase of 0.90% from the end of the previous year[6] - The total assets of the company as of March 31, 2024, were ¥2,946,600,361.23, slightly up from ¥2,920,451,107.53 at the end of 2023[14] - The total liabilities decreased to ¥1,155,505,033.80 from ¥1,211,097,697.17 at the end of 2023, indicating a reduction in financial obligations[14] - The company's equity attributable to shareholders increased to ¥1,539,903,554.84 from ¥1,470,311,172.51 at the end of 2023, indicating growth in shareholder value[14] Cash Flow - The net cash flow from operating activities was CNY 6,107,280.58, showing improvement as the previous year's figure was negative[5][7] - Cash flow from operating activities generated a net cash inflow of 6,107,280.58 RMB in Q1 2024, a significant improvement from a net outflow of -1,351,706.77 RMB in Q1 2023[21] - The company received 462,161,879.85 RMB in cash from sales of goods and services in Q1 2024, compared to 330,487,785.44 RMB in Q1 2023, marking a growth of about 39.8%[21] - Cash outflows for operating activities totaled 458,773,664.15 RMB in Q1 2024, compared to 339,248,689.86 RMB in Q1 2023, indicating an increase of approximately 35.3%[21] - The company reported a net cash outflow from investing activities of -10,385,541.40 RMB in Q1 2024, an improvement from -112,077,228.06 RMB in Q1 2023[21] - Cash inflow from financing activities in Q1 2024 was 24,200,000.00 RMB, with a net cash inflow of 16,865,454.05 RMB after financing outflows, compared to a net outflow of -2,223,791.67 RMB in Q1 2023[22] Shareholder Information - The company had a total of 22,032 common shareholders at the end of the reporting period[9] - The largest shareholder, Zhang Hai, holds 46.03% of the shares, with 94,145,600 shares pledged[10] Costs and Expenses - The total operating costs for Q1 2024 were ¥354,161,051.46, up 22.4% from ¥289,432,187.31 in Q1 2023[17] - Research and development expenses for Q1 2024 were ¥8,891,832.83, an increase of 77.5% compared to ¥5,014,006.28 in Q1 2023[17] Inventory and Receivables - The company reported a significant increase in accounts receivable, totaling ¥551,144,801.91 as of March 31, 2024, compared to ¥546,266,433.92 at the end of 2023[12] - The inventory level rose to ¥231,895,435.21 as of March 31, 2024, compared to ¥175,724,948.92 at the end of 2023, reflecting increased stock levels[12] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]

贵州三力制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 活动召开方式：网络远程方式。投资者可在上述召开时间，通过"全景 路演"（网址：http://rs.p5w.net），在线参与本次活动，公司将及时回答投资 者的提问。 投资者可于本公告发出之日起至 2024 年 5 月 7 日，通过微信关注"贵 州资本市场"公众号，发送关键词"提问"，即可进入专区提问。公司将在本次 说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）已于 2024 年 4 月 27 日在 上海证券交易所网站（http://www.sse.com.cn）上披露了《公司 2023 年年度 报告》及其摘要。为加强公司与投资者的交流互动，便于广大投资者更加全面 深入地了解公司 2023 年度的经营情况、公司治理及发展战略等。在贵州证监局 指导下，贵州证券业协会联合深圳市全景网络有限公司举办 2024 年贵州辖区上 市公司投资者集体接待日暨 2023 年度业绩说明会并征集相关问题。具体安排如 下： ...

贵州三力制药股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 第三届董事会第二十六次会议，审议通过了《关于提请股东大会授权董事会办理 以简易程序向特定对象发行股票的议案》，本议案尚需提交公司股东大会审议通 过。现将具体内容公告如下： 一、本次授权事项概述 为进一步推动公司业务的发展，公司拟提请股东大会依照《中华人民共和国 公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司证券发行注册管理办法》等法律法规、规范性文件及《公司章 程》等有关规定，授权董事会在不影响公司主营业务及保证公司财务安全的前提 下，择机办理向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末 净资产 20%的股票事宜，授权期限为本次授权相关议案经公司 2023 年年度股东 大会审议通过之日起至 2024 年度股东大会召开之日止。 二、本次授权事宜具体内容 证券代码：603439 证券简称：贵州三力 公告编号：2024-021 贵州三力制药股份有限公司 关于提请股东大会授权董事会办理以简易程序向特 定对象发行股票相关事宜的公告 本公司董事会及全体董事保证本公告内容不 ...

证券代码：603439 证券简称：贵州三力 公告编号：2024-017 2、2021 年 8 月 18 日至 2021 年 8 月 27 日，公司将本次拟激励对象的姓名 和职务进行了内部公示。公示期内，公司监事会未收到任何人对本次拟激励对象 贵州三力制药股份有限公司 关于 2021 年限制性股票激励计划首次授予部分第二 个解除限售期解除限售条件成就的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司将在办理完毕本次限制性股票解除限售手续后、股票上市流通前， 发布限制性股票解除限售暨上市公告，敬请投资者注意。 一、股权激励计划限制性股票批准及实施情况 （一）已履行的决策程序和信息披露情况 1、2021 年 8 月 16 日，贵州三力制药股份有限公司（以下简称"公司"）第 三届董事会第三次会议审议通过了《关于〈贵州三力制药股份有限公司 2021 年 限制性股票激励计划（草案）〉及其摘要的议案》（以下简称"激励计划"或"股 权激励计划"）。同日，公司第三届监事会第三次会议审议通过了上述议案并对 公司本次限制性 ...

北京国枫律师事务所 关于贵州三力制药股份有限公司 2021 年限制性股票激励计划之解除限售及回购注销部 分限制性股票相关事项的 法律意见书 国枫律证字[2021]AN186-6 号 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层 邮编; 100005 电话(Tel): 010－88004488/66090088 传真(Fax): 010—66090016 北京国枫律师事务所 关于贵州三力制药股份有限公司 2021 年限制性股票激励计划之解除限售及回购注销部分 限制性股票相关事项的 法律意见书 国枫律证字[2021]AN186-6 号 致:贵州三力制药股份有限公司 根据本所与贵州三力签署的《律师服务合同》,本所作为贵州三力本次股权 激励计划的专项法律顾问,已根据相关法律、法规和规范性文件的规定,并按照 律师行业公认的业务标准、道德规范和勤勉尽责精神出具了《北京国枫律师事务 所关于贵州三力制药股份有限公司2021年限制性股票激励计划(草案)的法律意 见书》《北京国枫律师事务所关于贵州三力制药股份有限公司2021年限制性股票 激励计 ...

附件 5 独立董事提名人声明与承诺 提名人贵州三力制药股份有限公司董事会，现提名陈世贵为贵州 三力制药股份有限公司第四届董事会独立董事候选人，并已充分了解 被提名人职业、学历、职称、详细的工作经历、全部兼职、有无重大 失信等不良记录等情况。被提名人已同意出任贵州三力制药股份有限 公司第四届董事会独立董事候选人（参见该独立董事候选人声明）。 提名人认为，被提名人具备独立董事任职资格，与贵州三力制药股份 有限公司之间不存在任何影响其独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有 5 年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 并已根据《上市公司高级管理人员培训工作指引》及相关规定取 得独立董事资格证书。 1 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 职（任职）问题 ...

贵州三力制药股份有限公司 2023 年度监事会工作报告 现将公司 2023 年度监事会工作情况汇报如下： 一、 监事会工作情况 2023 年公司监事依法履行职责，主要工作情况如下： | 序号 | 会议名称 | 召开时间 | 审议事项 | | --- | --- | --- | --- | | | 第三届监 | | 《公司 2022 年度监事会工作报告》 | | | | | 《公司 2022 年度财务决算报告》 | | 1 | 事会第十 | 2023/4/13 | | | | 二次会议 | | 《公司 2023 年度财务预算报告》 | | | | | 《关于 2022 年度利润分配方案的议案》 | 2023 年，贵州三力制药股份有限公司（以下简称"公司"）监事会严格按 照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上海证券交易所股票上市规则》（以 下简称"《股票上市规则》"）、《贵州三力制药股份有限公司章程》（以下简 称"《公司章程》"）、《贵州三力制药股份有限公司监事会议事规则》等有关 法律法规、规范性文件以及公司制度的规定，本着对全体股东负责的 ...

贵州三力制药股份有限公司 第五条 审计委员会设召集人一名，须为会计专业人士且为独立董事，负责主持委员会工 作。召集人在委员会内选举产生，并报请董事会批准。 第六条 审计委员会任期与董事会一致，委员任期届满后，连选可以连任。 贵州三力制药股份有限公司 董事会审计委员会工作细则 （2024 年修订版） 第一章 总 则 第一条 为强化贵州三力制药股份有限公司（以下简称"公司"）董事会决策功能，做到事 前审计、专业审计，确保对公司财务收支和各项经营活动的有效监督，完善公司法人治理结 构，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董事管理办 法》《上市公司治理准则》《上海证券交易所上市公司自律监管指引第1号——规范运作》等 法律法规、规范性文件以及《贵州三力制药股份有限公司章程》（以下简称"《公司章 程》"）等有关规定，公司特设立董事会审计委员会（以下简称"审计委员会"），并制定董 事会审计委员会工作细则（以下简称"本工作细则"）。 第二条 审计委员会是董事会下设的专门工作机构，主要负责审核公司财务信息及其披露、 监督及评估内外部审计工作和内部控制。 第二章 审计委员会的产生与组成 第三条 审计 ...